Skip to content

Replimune Group REPL Finance Lease Liabilities

Finance Lease Liabilities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$0-100%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$213K
Incyte logo
IncyteINCY
$29.41M-9.9%
Moderna logo
ModernaMRNA
$13M-62.9%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's finance lease liabilities?
Replimune Group (REPL) reported finance lease liabilities of $22.13M in Q4 2025.
How has Replimune Group's finance lease liabilities changed year-over-year?
Replimune Group's finance lease liabilities decreased by 3.4% year-over-year, from $22.91M to $22.13M.
What is the long-term trend for Replimune Group's finance lease liabilities?
Over 4 years (2021 to 2025), Replimune Group's finance lease liabilities has grown at a -2.1% compound annual growth rate (CAGR), from $24.75M to $22.73M.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.